US Patent

US8106183 — Process for preparing an A2A-adenosine receptor agonist and its polymorphs

Composition of Matter · Assigned to Gilead Sciences Inc · Expires 2027-02-02 · 1y remaining

Vulnerability score 27/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects a process for synthesizing an A2A-adenosine receptor agonist and methods for isolating specific polymorphs of that compound.

USPTO Abstract

Disclosed is a synthesis suitable for large scale manufacture of an A 2A -adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.

Drugs covered by this patent

Patent Metadata

Patent number
US8106183
Jurisdiction
US
Classification
Composition of Matter
Expires
2027-02-02
Drug substance claim
Yes
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.